What definitive merger agreement has Talecris made with CSL?
“Talecris Biotherapeutics, Inc. (www.talecris.com) today announced that it has signed a definitive merger agreement with CSL under which CSL has agreed to acquire Talecris for $3.1 billion in cash. This amount includes net debt, which as of June 30, 2008 was approximately $1.2 billion, implying an equity value as of that date of about $1.9 billion. The combination of Talecris and CSL will result in: a combined company with one of the broadest portfolios in the plasma-derived therapeutics industry with key products in each plasma therapeutic area; one of the most robust and efficient plasma collection capabilities in the industry, to better assure supply of plasma for manufacturing essential therapies; expanded and integrated manufacturing with greater efficiency and improved ability to supply therapies; an enhanced R&D pipeline; operating efficiencies that will facilitate further investment in R&D, quality, compliance and plasma collection; and improved and more reliable supply of ther
Talecris Enters into Definitive Merger Agreement with CSL RESEARCH TRIANGLE PARK, N.C. (August 12, 2008) —Talecris Biotherapeutics, Inc. (www.talecris.com) today announced that it has signed a definitive merger agreement with CSL under which CSL has agreed to acquire Talecris for $3.1 billion in cash. This amount includes net debt, which as of June 30, 2008 was approximately $1.2 billion, implying an equity value as of that date of about $1.9 billion. The combination of Talecris and CSL will result in: * a combined company with one of the broadest portfolios in the plasma-derived therapeutics industry with key products in each plasma therapeutic area; * one of the most robust and efficient plasma collection capabilities in the industry, to better assure supply of plasma for manufacturing essential therapies; * expanded and integrated manufacturing with greater efficiency and improved ability to supply therapies; * an enhanced R&D pipeline; * operating efficiencies that will facilitate
